

Magdalena M Suchacz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3444408/publications.pdf>

Version: 2024-02-01

32
papers

135
citations

1478505

6
h-index

1281871

11
g-index

33
all docs

33
docs citations

33
times ranked

250
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma HIV-RNA Is the Key Determinant of Long-Term Antibody Persistence After Yellow Fever Immunization in a Cohort of 364 HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 360-367.	2.1	37
2	Impact of Combined Antiretroviral Therapy on Metabolic Syndrome Components in Adult People Living with HIV: A Literature Review. <i>Viruses</i> , 2022, 14, 122.	3.3	19
3	Long-term trends in HIV care entry: over 15 years of clinical experience from Poland. <i>HIV Medicine</i> , 2019, 20, 581-590.	2.2	12
4	Comparative Analysis of the New Chronic Kidney Disease Epidemiology Collaboration and the Modification of Diet in Renal Disease Equations for Estimation of Glomerular Filtration Rate in HIV Type 1-Infected Subjects. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 809-813.	1.1	8
5	Evaluation of endothelial function and arterial stiffness in HIV-infected patients: a pilot study. <i>Kardiologia Polska</i> , 2015, 73, 344-351.	0.6	8
6	Signal transduction pathways in liver and the influence of hepatitis C virus infection on their activities. <i>World Journal of Gastroenterology</i> , 2009, 15, 2184.	3.3	6
7	Cowpox: How dangerous could it be for humans? Case report. <i>International Journal of Infectious Diseases</i> , 2021, 104, 239-241.	3.3	6
8	HCV coinfection possibly promotes left ventricular dysfunction development. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1.	1.6	5
9	Pigment epithelium-derived factor and matrix metalloproteinase-9 in liver cirrhosis. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 375.	1.1	5
10	Once-daily single tablet regimen of tenofovir/emtricitabine/efavirenz—Potent, safe and convenient approach to combined antiretroviral therapy. <i>HIV and AIDS Review</i> , 2011, 10, 38-39.	0.2	4
11	The role of serum I-FABP concentration in assessment of small intestine mucosa among HIV-infected patients. <i>European Journal of Inflammation</i> , 2015, 13, 75-81.	0.5	4
12	Generalized Posttransplant Kaposi Sarcoma without Mucocutaneous Manifestations in the First Liver Transplantation in an HIV-Positive Patient in Poland: A Case Report and Review of Literature. <i>Annals of Transplantation</i> , 2016, 21, 683-688.	0.9	4
13	The Presence of Either Typical or Atypical Radiological Changes Predicts Poor COVID-19 Outcomes in HIV-Positive Patients from a Multinational Observational Study: Data from Euroguidelines in Central and Eastern Europe Network Group. <i>Viruses</i> , 2022, 14, 972.	3.3	3
14	Procalcitonin as a Biomarker of the Early Stage of Bacterial Infections in HIV/AIDS Patients. <i>European Journal of Inflammation</i> , 2014, 12, 305-313.	0.5	2
15	High platelet count and high low-density lipoprotein level may be an independent marker of increased arterial stiffness in adult HIV-infected persons. <i>HIV and AIDS Review</i> , 2019, 18, 14-18.	0.2	2
16	Risk Factors of Hypovitaminosis D in HIV-Infected Patients on Suppressive Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 676-680.	1.1	2
17	Significance of Vascular Cell Adhesion Molecule-1 and Tumor Necrosis Factor-Alpha in HIV-Infected Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 514.	2.4	2
18	Slowly progressing cutaneous T-cell lymphoma in HIV infected individual. <i>HIV and AIDS Review</i> , 2007, 6, 33-35.	0.2	1

#	ARTICLE	IF	CITATIONS
19	Integrase inhibitors as a new class of ARV treatment. HIV and AIDS Review, 2007, 6, 10-14.	0.2	1
20	Serum concentrations of β -defensins in patients with different stages of HIV-infection. HIV and AIDS Review, 2007, 6, 20-22.	0.2	1
21	Raltegravir " a new agent in HIV-infected treatment-naive patients?. HIV and AIDS Review, 2009, 8, 5-7.	0.2	1
22	Is Ritonavir-boosted Protease Inhibitors (PIs/r) monotherapy noninferior to classic combined antiretroviral therapy (cART)?. HIV and AIDS Review, 2010, 9, 61-64.	0.2	1
23	Zmiana terapii antyretrowirusowej. HIV and AIDS Review, 2013, 12, 113-115.	0.2	1
24	Cystatin C as a new biomarker of renal dysfunction in HIV-1 infected patients " preliminary report. HIV and AIDS Review, 2008, 7, 22-25.	0.2	0
25	Boosted darunavir as a new therapeutic option for treatment-naive HIV-infected patients. HIV and AIDS Review, 2009, 8, 5-7.	0.2	0
26	Once-daily boosted darunavir as a new therapeutic option for treatment-experienced HIV-infected patients. HIV and AIDS Review, 2011, 10, 54-55.	0.2	0
27	Metabolic abnormalities and cardiovascular risk in HIV-infected cohort of patients treated with protease inhibitors. HIV and AIDS Review, 2015, 14, 22-27.	0.2	0
28	Sociological analysis of the content of media coverage on the "Social Committee for AIDS (SKA)" Facebook profile. HIV and AIDS Review, 2019, 18, 70-73.	0.2	0
29	Outbreaks of hepatitis A in Poland are often connected with other infections. HIV and AIDS Review, 2019, 18, 40-43.	0.2	0
30	The effects of CD4 nadirs on vessel stiffness in HIV patients undergoing antiretroviral therapy. Kardiologia Polska, 2017, 75, 749-757.	0.6	0
31	QTc interval prolongation in asymptomatic HIV " infected patients treated and untreated with antiretroviral therapy. Postepy Higieny I Medycyny Doswiadczonej, 2019, 73, 225-231.	0.1	0
32	HIV-infected patients on combined antiretroviral treatment had a similar level of arterial stiffness to the patients with ST-segment elevation myocardial infarction. Kardiologia Polska, 2022, 80, 208-210.	0.6	0